Title: Early Phase II Study on BNCT in Metastatic Malignant Melanoma Using the Boron Carrier BPA (EORTC Protocol 11011)
Authors: SAUERWEIN WOLFGANGMOSS RAYMONDSTECHER-RASMUSSEN FinnNIEVAART VICTOR ALEXANDERGRABBE StephanHEIMANS JanCOLLETTE LaurenceVAN LOENEN ArieBUEHRMANN SandraROCA ANTOANETAHOVING AntonRASSOW Juergen
Other Contributors: WITTIG ANDREA
Citation: Advances in Neutron Capture Therapy 2006 p. 284-287
Publisher: International Society for Neutron Capture Therapy: ISNCT
Publication Year: 2006
JRC Publication N°: JRC35042
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC35042
Type: Contributions to Conferences
Abstract: The aim of the trial is to examine the clinical response of metastatic melanoma following BNCT with BPA. The trial contains an optional biodistribution sub-study , which is done if operable metastases are removed prior BNCT. BNCT is applied in 2 fractions at the HFR in Petten. In cases of diffuse brain metastases the whole brain is irradiated homogeneously using 5 irradiation beams from different directions. Up to now 4 patients suffering from multiple brain metastases (more than 20) have been included. In all cases we observed a partial response or no change in the irradiated volume. However, none of the patients survived more than 3 months. The pharmacokinetic of the BPA can be predicted very precisely using a two-compartment model. The treatment can be performed safely.
JRC Institute:Institute for Energy and Transport

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.